Antisense therapy specific to mutated K-ras gene in hamster pancreatic cancer model. Can it inhibit the growth of 5-FU and MMC-resistant metastatic anb remetastic cell lines?

In Vivo

Volumn 18, Issue 2, 2004, Pages 113-118

  Morioka, Cíntia Yoko ^a,b   Saito, Seijo ^b   Machado, Marcel Cerqueria Cesar ^a   Ohzawa, Kouji ^b   Kubrusly, Márcia Saldanha ^a   Monteiro Cunha, José Eduardo ^a   Watanabe, Akiharu ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Antisense oligonucleotides; Drug resistance; K ras point mutation; Metastasis; Pancreatic cancer; Syrian golden hamsters

Indexed keywords

AGAROSE; ANTISENSE OLIGONUCLEOTIDE; FLUOROURACIL; MITOMYCIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CONTROLLED STUDY; GENE MUTATION; GROWTH INHIBITION; HAMSTER; IC 50; LIVER METASTASIS; MALE; NONHUMAN; ONCOGENE K RAS; PANCREAS CANCER;

EID: 1842841750     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, Abrams RA, Laheru D, Jaffee EM, Hidalgo M and Yeo CJ: Pancreatic cancer. Curr Probl Cancer 26: 176-275, 2002.
2. Kern SE, Hruban RH, Hidalgo M and Yeo CJ: An introduction to pancreatic adenocarcinoma genetics, pathology, and therapy. Cancer Biol Ther 1: 607-613, 2002.
3. US Mortality Public Use Date Tapes 1960-1996. US Mortality Volumes 1930-1959. National Center for Health Statistics. Centers for Disease Control and Prevention, 1999. URL:http://www.acrs.org
4. Spanknebel K and Conlon KC: Advances in the surgical management of pancreatic cancer. Cancer J 7: 312-323, 2001.
5. Caldas C and Kern SE: K-ras mutations and pancreatic adenocarcinoma. Int J Pancreatol 18: 1-6, 1995.
6. Hahn SA and Kern SE: Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 75: 857-869, 1995.
7. Sakorafas GH, Tsiotou AG and Tsiotou GG: Molecular biology of pancreatic cancer: oncogenes, tumor suppressor genes, growth factors and their receptors from a clinical perspective. Cancer Treat Rev 26: 29-52, 2000.
8. Hruban RH, Wilentz Re and Kern SE: Genetic progression in the pancreatic ducts. Am J Pathol 156: 1821-1825, 2000.
9. Ellis CA and Clark G: The importance of being K-ras. Cell Sign 12:425-434, 2000.
10. Kubrusly MS, Cunha JE, Bacchella T, Abdo EE, Jukemura J, Penteado S, Morioka CY, de Souza LJ and Machado MC: Detection of K-ras point mutation at codon 12 in pancreatic diseases: a study in a Brazilian casuistic. JOP 3: 144-151, 2002.
11. Cerny WL, Mangold KA and Scarpelli DG: K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamsters. Cancer Res 52: 4507-4513, 1992.
12. Tsutsumi M, Murakami Y, Kondoh S, Tsujiuchi T, Hohnoki K, Horiguchi K, Noguchi O, Kobayashi E, Okita S, Sekiya T et al: Comparison of K-ras oncogene activation in pancreatic duct carcinomas and cholangiocarcinomas induced in hamsters by N-nitrosobis(2-hydroxypropyl)amine. Jpn J Cancer Res 84: 956-960, 1993.
13. Tsutsumi M Kondoh S, Noguchi O, Horiguchi K, Kobayashi E, Okita S, Ohashi K, Honoki K, Tsujiuchi T and Konishi Y: K-ras gene mutation in early ductal lesions induced in a rapid production model for pancreatic carcinomas in Syrian hamsters. Jpn J Cancer Res 84: 1101-1105, 1993.
14. Konishi Y, Tsutsumi M and Tsujiuchi T: Mechanistic analysis of pancreatic ductal carcinogenesis in hamsters. Pancreas 16: 300-306, 1998.
15. Mangold KA, Hubchak S, Mangino MM, Laconi S and Scarpelli DG: In vitro carcinogenesis of hamster pancreatic duct cells: cellular and molecular alterations. Carcinogenesis 15: 1979-1984, 1994.
16. Chang KW, Laconi S, Mangold KA, Hubchak S and Scarpelli DG: Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas. Cancer Res 55: 2560-2568, 1995.
17. Morioka CY, Saito S, Ohzawa K and Watanabe A: Homologous orthotopic implantation models of pancreatic ductal cancer in Syrian golden hamsters: which is better for metastasis research--cell implantation or tissue implantation? Pancreas 20: 152-157, 2000.
18. Morioka CY, Saito S, Kita K and Watanabe A: Curative resection of orthotopically implanted pancreatic cancer in Syrian golden hamsters. Int J Pancreatol 28: 207-213, 2000.
19. Morioka CY, Saito S, Ohzawa K Asano S, Hibino Y, Nakada Y, Kita KI and Watanabe A: Subcutaneously inoculated cells and implanted pancreatic cancer tissue show different patterns of metastases in Syrian golden hamsters. JOP 1: 183-90, 2000.
20. Kerbel RS, Kobayashi H and Graham CH: Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 56: 37-47, 1994.
21. Fidler IJ: Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 43: S3-10, 1999.
22. Alemany R, Ruan S, Kataoka M, Koch PE, Mukhopadhyay T, Cristiano RJ, Roth JA and Zhang WW: Growth inhibitory effect of anti K-ras adenovirus on lung cancer cells. Cancer Gene Ther 3: 296-301, 1996.
23. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugiyama T and Terada M: Supression of K-ras P21 levels leading to growth inhibition of pancreatic cancer cell lines with K-ras mutations but not those without K-ras mutation. Mol Carcinog 20: 251-258, 1997.
24. Aoki K, Yoshida T, Sugimura T and Terada M: Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55: 3810-3816, 1995.
25. Kita K, Saito S, Morioka CY and Watanabe A: Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 80: 553-558, 1999.
26. Nakada Y, Saito S, Ohzawa & Morioka CY, Kita K. Minemura M, Takahara T and Watanabe A: Antisense oligonucleotides specific to mutated K-ras genes inhibit invasiveness of human pancreatic cancer cell lines. Pancreatology 1: 314-319, 2001.
27. Saito S, Nishimura N, Kubota Y, Yamazaki K, Shibuya T and Sasaki H: Establishment and characterization of a cultured cell line derived from nitrosamine-induced pancreatic ductal adenocarcinoma in Syrian golden hamsters. Gastroenterol Jpn 23: 183-194, 1988.
28. Morioka CY, Saito S and Watanabe A: "Return trip" metastases from the liver to the pancreas in Syrian golden hamsters. In Vivo 14: 467-469, 2000.
29. Abe R, Ueo H and Akiyoshi T: Evaluation of MTT assay in agarose for chemosensitivity testing of human cancers: comparison with MTT assay. Oncology 51: 416-425, 1994.
30. Andren-Sandberg A and Neoptolemos JP: Resection for pancreatic cancer in the new millennium. Pancreatology 2: 431-439, 2002.
31. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J and Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221: 721-731; discussion 731-733, 1995.
32. el-Rayes BF, Shields AF, Vaitkevicius V and Philip PA: Developments in the systemic therapy of pancreatic cancer. Cancer Invest 21: 73-86, 2003.
33. Haller DG: Future directions in the treatment of pancreatic cancer. Semin Oncol 29: 31-39, 2002.